"Od monitorovania hladiny f\u00FAzneho g\u00E9nu Bcr/Abl u pacienta s chronickou ymeloidnou leuk\u00E9miou k odha\u013Eovaniu rezistencie k imatinibu - kazuistika" . "Ro\u017Emanov\u00E1, \u0160\u00E1rka" . . "Faber, Edgar" . "13" . . "Od monitorovania hladiny f\u00FAzneho g\u00E9nu Bcr/Abl u pacienta s chronickou ymeloidnou leuk\u00E9miou k odha\u013Eovaniu rezistencie k imatinibu - kazuistika" . "1213-5763" . "There is the case report of 63-years old patient with Ph1 positive chronic myeloid leukaemia (CML) who is treated with 400 mg of imatinib daily. It is because of the secondary cytogenetic resistance to interferon alpha after two years from diagnosis. After initial cytogenetic response (10 % Bcr/Abl positive cells detected by bone marrow interphase FISH examination after 3 months and 1 log decrease in quantitative RT-PCR after 6 month of treatment) there is the cytogenetic progression in one year with failure of the response to the escalated dosage 800 mg daily. It leads to the suspicion of imatinib resistance. In vitro tests confirm it: there is a high expression of WT1 gene, the presence of phosphorylated CRKL and detection of T315I mutation in Abl kinase domain. This article is aimed at detection of imatinib resistance in case of suspicion and should also show the review of the new treatment modalities. The resistance detection is important from clinical point of view. It allows to stop the therapy"@en . . "438824" . . . "10"^^ . "Od monitorovania hladiny f\u00FAzneho g\u00E9nu Bcr/Abl u pacienta s chronickou ymeloidnou leuk\u00E9miou k odha\u013Eovaniu rezistencie k imatinibu - kazuistika"@cs . . "P(GA301/04/1239), P(NR7870), Z(MSM6198959205)" . "Bcr/Abl fusion gene; WT1 gene; quantitative RT-PCR; tyrosine kinase inhibotors; T315I mutation"@en . . "From the monitoring of Vcr/Abl fusion gene level in patient with chronic myeloid leukemia to the imatinib resitance detection - case report"@en . "Nau\u0161ov\u00E1, Jana" . "Divok\u00FD, Vladim\u00EDr" . . "Indr\u00E1k, Karel" . "Od monitorovania hladiny f\u00FAzneho g\u00E9nu Bcr/Abl u pacienta s chronickou ymeloidnou leuk\u00E9miou k odha\u013Eovaniu rezistencie k imatinibu - kazuistika"@cs . "Soln\u00E1, Ren\u00E1ta" . "Transfuze a hematologie dnes" . . . . "CZ - \u010Cesk\u00E1 republika" . . "From the monitoring of Vcr/Abl fusion gene level in patient with chronic myeloid leukemia to the imatinib resitance detection - case report"@en . . . . . "RIV/61989592:15110/07:00003565" . . "15110" . "Popisujeme kazuistiku 63-ro\u010Dn\u00E9ho pacienta s Ph1 pozit\u00EDvnou chronickou myeloidnou leuk\u00E9miou (CML), u ktor\u00E9ho bola pre sekund\u00E1rnu cytogenetick\u00FA rezistenciu na intefer\u00F3n alfa po dvoch rokoch od stanovenia diagn\u00F3zy indikovan\u00E1 lie\u010Dba imatinibom v d\u00E1vke 400 mg denne. Po inici\u00E1lnej cytogenetickej odpovedi (10 % Bcr/Abl pozit\u00EDvnych buniek pri vy\u0161etren\u00ED kostnej drene met\u00F3dou interf\u00E1zovej FISH po 3 meisacoch a pokles o 1 log v kvantitat\u00EDvnej RT-PCR po \u0161iestich mesiacoch lie\u010Dby), doch\u00E1dza po roku lie\u010Dby k cytogenetickej progresii s neodstato\u010Dnou odpove\u010Fou i na eskalovan\u00FA d\u00E1vku imatinibu 800 mg denne. To vedie k podozreniu na rezistenci k imatinibu. In vitro testy to potvrdzuj\u00FA: vysok\u00E1 expresia WT1 g\u00E9nu, pozitivita testu na fosforylovan\u00FD CRKL a odhalenie mut\u00E1cie T315I v oblasti ABL kin\u00E1zovej dom\u00E9ny. Cielom \u010Dl\u00E1nku je na\u010Drtn\u00FAt kroky, ktor\u00E9 by mali nasledova\u0165 pri podozren\u00ED na rezistenciu k imatinibu a poskytn\u00FA\u0165 prehlad dal\u0161\u00EDch lie\u010Debn\u00FDch mo\u017Enost\u00ED. Ur\u010Denie rezistenci m\u00E1 klinick\u00FD vznam, preto\u017Ee na jednej strane umo\u017E\u0148u" . "RIV/61989592:15110/07:00003565!RIV08-MZ0-15110___" . . . . . "27-31" . . "[CEE9CBA0DED1]" . "Popisujeme kazuistiku 63-ro\u010Dn\u00E9ho pacienta s Ph1 pozit\u00EDvnou chronickou myeloidnou leuk\u00E9miou (CML), u ktor\u00E9ho bola pre sekund\u00E1rnu cytogenetick\u00FA rezistenciu na intefer\u00F3n alfa po dvoch rokoch od stanovenia diagn\u00F3zy indikovan\u00E1 lie\u010Dba imatinibom v d\u00E1vke 400 mg denne. Po inici\u00E1lnej cytogenetickej odpovedi (10 % Bcr/Abl pozit\u00EDvnych buniek pri vy\u0161etren\u00ED kostnej drene met\u00F3dou interf\u00E1zovej FISH po 3 meisacoch a pokles o 1 log v kvantitat\u00EDvnej RT-PCR po \u0161iestich mesiacoch lie\u010Dby), doch\u00E1dza po roku lie\u010Dby k cytogenetickej progresii s neodstato\u010Dnou odpove\u010Fou i na eskalovan\u00FA d\u00E1vku imatinibu 800 mg denne. To vedie k podozreniu na rezistenci k imatinibu. In vitro testy to potvrdzuj\u00FA: vysok\u00E1 expresia WT1 g\u00E9nu, pozitivita testu na fosforylovan\u00FD CRKL a odhalenie mut\u00E1cie T315I v oblasti ABL kin\u00E1zovej dom\u00E9ny. Cielom \u010Dl\u00E1nku je na\u010Drtn\u00FAt kroky, ktor\u00E9 by mali nasledova\u0165 pri podozren\u00ED na rezistenciu k imatinibu a poskytn\u00FA\u0165 prehlad dal\u0161\u00EDch lie\u010Debn\u00FDch mo\u017Enost\u00ED. Ur\u010Denie rezistenci m\u00E1 klinick\u00FD vznam, preto\u017Ee na jednej strane umo\u017E\u0148u"@cs . "5"^^ . . "Brejcha, M." . "Jaro\u0161ov\u00E1, Marie" . "1" . . . . "Plach\u00FD, Radek" . "7"^^ . "Roho\u0148, Peter" .